Richard Fama and Kristin Keehan contributed an article to Cannabis Business Executive discussing the high demands of CBD-containing products along with concerns from the FDA. Fortunately, the FDA has assembled an internal working group to address these unanswered questions and propose potential pathways for marketing and selling CBD products, though such pathways do not appear to be forthcoming in the near future.
To read this article, click here.